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Background: Continuing developments in genetic testing technology together with research revealing
gene-disease associations have brought closer the potential for genetic screening of populations. A major concern,
as with any screening programme, is the response of the patient to the findings of screening, whether the
outcome is positive or negative. Such concern is heightened for genetic testing, which it is feared may elicit
stronger reactions than non-genetic testing.
Methods: This paper draws on thematic analysis of 113 semi-structured interviews with 39 patients being tested
for familial hypercholesterolaemia (FH), an inherited predisposition to early-onset heart disease. It examines the
impact of disease risk assessments based on both genetic and non-genetic information, or solely non-genetic
information.
Results: The impact of diagnostic testing did not seem to vary according to whether or not genetic information
was used. More generally, being given a positive or negative diagnosis of FH had minimal discernible impact on
people's lives as they maintained the continuity of their beliefs and behaviour.
Conclusions: The results suggest that concerns about the use of genetic testing in this context are unfounded,
a conclusion that echoes findings from studies in this and other health contexts.
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New genetic testing technologies and reported gene-
disease associations have resulted in the appearance of
many genetic testing services, particularly from the pri-
vate sector (e.g. 23andMe [1]; Navigenics [2]). Whilst
there has been criticism of the value of some of the lat-
ter [3], high expectations about the beneficial effects of
providing such information are also in evidence [4].
Some commentators have suggested that in healthcare
settings genetic risk factors are often perceived as carry-
ing more weight for practitioners and patients than
equivalent environmental factors [5]. Such a position is
in accordance with a historic biomedical discourse in
which patients with a genetic mutation develop a given* Correspondence: theresa.marteau@kcl.ac.uk
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reproduction in any medium, provided the orillness, informed by examples such as Huntington’s dis-
ease and cystic fibrosis. Previous studies of genetic dis-
ease risk assessment, however, report mixed evidence
regarding its impact. Whilst a systematic review of the
psychological consequences of predictive genetic testing
for Huntington’s disease and breast cancer found no evi-
dence of adverse experiences [6], the significance of the
penetrance of a genetic variant, i.e. the extent to which
the genotype determines the phenotype disease state,
has been highlighted in other studies. As such, genetic
tests with high predictive value are regarded as different
and may have more potent effects [7,8]. It has also been
suggested that patients typically feel more involved with
their condition when it is presented as having a genetic
basis [9]. Furthermore, it has been found that the prov-
enance of risk information influences the responses that
are adjudged to be most effective, with provision of gen-
etic risk information to individuals being associated withal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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responses, such as taking medication, versus behavioural
responses, such as altering levels of physical activity or
diet [10,11].
Most of the evidence for the impact of genetic testing
has involved studies of those with ‘positive’ results; there
has been some, though less, research on those receiving
a negative result. Yet these studies have not always been
able to disentangle the impact of the genetic test itself
from the diagnosis. For example, for many years the
diagnosis of familial hypercholerosterolaemia (FH) has
been made from the clinical picture of the disease rather
than from a specific genetic test. As more recently gen-
etic testing has been introduced in some centres, it is
now possible to study the impact of the method of test-
ing on patients’ response to such a diagnosis.Condition and clinical context
Familial hypercholesterolaemia is, as its name implies,
an inherited genetic condition that results in high blood
cholesterol and a recognised risk factor for heart disease.
The importance of diagnosis is emphasised by the esti-
mate that heterozygous FH leads to a greater than 50%
risk of coronary heart disease in men by the age of
50 years and at least 30% in women by the age of
60 years [12]. No single mutation is regarded as suffi-
ciently frequent to justify population screening except
for individuals whose families have been identified as
carrying the mutation. Diagnosis has traditionally been
based on phenotypic factors, namely, family history of
raised cholesterol and early coronary heart disease, and
on clinical symptoms, including tendon xanthoma [13].
Patients are rarely seen in dedicated genetic clinics and
instead are usually seen in lipid clinics that manage
patients with abnormal blood lipids, irrespective of ori-
gin. Latterly, however, some clinics have begun to intro-
duce genetic testing. This approach to testing has
advantages in terms of increased accuracy and theGenetic risk assessment
Positive test result 
 Negative test result 
       Genetic positive          
       Genetic negative         
Figure 1 Participant sampling categorisation by diagnosis.potential for early diagnosis, but also disadvantages, such
as cost and the potential impact on patients [14].
Qualitative studies that have focused on FH suggest a
positive diagnosis for FH does not evoke substantive
effects in patients. Senior and colleagues [15] found that
those receiving genetic risk information were likely to
see their results as routine and holding no greater sig-
nificance than other risk factors. This is consistent with
the suggestion that existing lay models readily accom-
modate genetic information as individuals already expect
a familial component to cardiovascular disease [16].
Weiner and Durrington [17] found that individuals
screened for FH do not tend to view their genes or her-
edity as having a major deterministic role in heart dis-
ease, or see an FH diagnosis as problematic in the long
term. Existing evidence therefore suggests that there
may be no systematic impact of the diagnosis within the
context of FH risk assessment.
Yet receiving a genetic diagnosis and undergoing a gen-
etic test are two different experiences and this study
sought to disentangle their respective impacts by examin-
ing groups of patients with different experiences of each.Methods
While a qualitative approach was adopted for data col-
lection and analysis, sampling was based on a factorial
design which recruited groups of patients based on their
experiences of genetic or non-genetic testing and nega-
tive or positive test results.
Clinic nurses invited all patients who were first or sec-
ond degree relatives of probands with familial hyperchol-
esterolaemia (FH) and who attended a specialist lipid
clinic in one of 11 participating hospitals in the UK for
diagnostic testing of FH to be contacted by the study
team. Those who agreed were informed about the nature
of the study and written consent was obtained. The sam-
pling strategy aimed to recruit 40 patients in total, with
10 from each diagnostic category or cell (see Figure 1).       Non-genetic risk assessment 
       Non-genetic positive 
       Non-genetic negative 
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went baseline interviews before testing and were then
followed up to assess their reaction to both the form of
the test and the result. Follow-up was therefore selective
to ensure the required numbers (10 patients) in each of
the factorial cells. In the event, ten patients were
recruited from the non-genetic negative diagnosis cat-
egory, with nine, nine and eleven recruited from the
other categories (respectively non-genetic positive, gen-
etic negative and genetic positive), making 39 patients in
total.
Characteristics of study participants are presented in
Table 1. We did not systematically gather detailed infor-
mation on participants’ unique clinical histories and
pathways leading to testing at the clinic, but patients
were usually identified in primary care or in cardiology
services through assessment of symptoms and family
history, typically involving a cholesterol test. They were
then referred to specialist services for further assessment
and diagnosis. As a result of the prior investigations,
many patients were likely to expect a definitive FH diag-
nosis from the specialist service at the time of their re-
ferral. Participants in this study were therefore asked
whether they had received cholesterol tests in the past
and what FH test result they expected. It is apparent
from Table 1 that the majority of participants in all cat-
egories had received a cholesterol test previously, con-
sistent with the fact that participants typically accurately
predicted their diagnosis.Table 1 Participant characteristics by familial hypercholestero
DNA diagnosis DNA diagn
positive negative





White British 9 5
Asian British 1 2










Uncertain 2 5Consenting patients were contacted for three tele-
phone interviews each: following the initial consultation
but before receiving the results of diagnostic testing; im-
mediately after receipt of the test results; and six months
later. In total, 113 separate interviews were conducted
and used for the analysis, with four intended follow-up
interviews unable to be completed due to the patients
being lost to contact.
All interviews were transcribed by an external tran-
scription service and analysed using thematic analysis
managed with NVivo computer software [18]. Tran-
scripts were analysed separately by two members of the
research team, with a third member of the team acting
to oversee the integration of findings when analyses were
subsequently compared and discussed. There was a high
level of comparability between the emergent themes that
were identified. The determination of themes drew
broadly from all sampling categories. Respondents are
identified in the text as follows: undergoing risk assess-
ment that included genetic testing (DNA) or risk assess-
ment not including genetic testing (NonDNA); diagnosis
(positive or negative); participant number by site (01–
11); timepoint of interview (1, 2 or 3).
The study had ethical approval from Huntingdon Re-
search Ethics Committee (06/Q0104/16).
Results
Five principal themes emerged in the analysis. These are
described below.laemia test result received
















Hollands et al. BMC Medical Genetics 2012, 13:87 Page 4 of 9
http://www.biomedcentral.com/1471-2350/13/87Continuity and normalisation
The main feature of patients’ responses to either a posi-
tive or negative diagnosis across all four groups was one
of normalisation and continuity, that is, the results of
the tests offered no significant challenge to their iden-
tities or their lives in the future. This was reflected both
in the way they regarded the test results and more gen-
erally the implications of a diagnosis.
Many patients in all four categories had realistic
expectations of the results of diagnostic testing (i.e. they
had an accurate sense of the likely diagnosis) whether it
included a genetic test or not. None of the patients who
ultimately received positive test results had expected a
negative test result, prior to receiving their results, and
vice versa. Having had relatives with FH or high choles-
terol they knew they were at risk, had undergone choles-
terol tests over preceding years, and often talked about
the familial context of their risk. If these earlier choles-
terol tests had revealed high values then they had
assumed that, like their relatives, they had FH. Con-
versely, if their cholesterol values had been within the
normal range, they had assumed they were unaffected.
Hence, very few patients expressed much surprise at the
outcome of their diagnostic assessments. This did not
vary between those whose diagnostic assessments
included a genetic test and those whose did not.
Prior to receiving their results, patients typically
expressed confidence in anticipating the likely outcome,
and indicated that they had already accepted it:
(Interviewer: How have you been thinking about the
test before coming to the hospital?) I’ve not really been
too concerned about it to be honest. I mean I’ll be
honest, last time I had my cholesterol checked it was
3.5, it was low. I think my brother’s got it because he
tends to have a lot of the symptoms.
(NonDNA, negative, 01, time 1)
(Interviewer: So how would you feel if the results that
come back show that you do have FH?) Well I would
know that anyway so it wouldn’t surprise me.
(NonDNA, positive, 09, time 1)
I would be a bit shocked actually because I’m so
convinced I don’t have it.
(DNA, negative, 03, time 1)
This expectation of what the test result might reveal
was also reflected in later responses to the test result.
I wasn’t surprised because I didn’t really think I had it
to be honest.(NonDNA, negative, 01, time 2)
I thought they would be anyway so it just. . . I was
pleased obviously but deep down I thought that would
be the case.
(DNA, negative, 03, time 2)
Beforehand I knew they would be clear anyway. I
haven’t had any problems of history with these sort of
problems anyway so I was fairly confident they were
going to be alright.
(DNA, negative, 04, time 2)
I wasn’t surprised. I know there has been a family
history of it so it was a 50/50 chance of me having it
or not having it.
(DNA, positive, 01, time 2)
It just confirmed what I expected really. I need to get
my blood tests done again for the cholesterol and just
keep an eye on it.
(DNA, positive, 02, time 2)
A sense of acceptance of the implications of the results
for people’s lives and their ongoing health was also appar-
ent in responses both before and after receiving the test
results. Some patients, however, did propose some small
adjustments even though the results had been predictable.
If my body’s producing it then I’ll just have to learn to
live with it really and it’s not stopping me from doing
my everyday life. I can still manage to go to work and
you know look after my family etc. so it’s not
something stopping me in any way. I don’t know I
think I’ll just be the same really.
(NonDNA, positive, 08, time 1)
I don’t think it would have a major impact, I’d just
have to change my lifestyle slightly, eat a bit more
healthily.
(DNA, negative, 05, time 1)
It wouldn’t have that much of an impact, like change
my life that much. It would worry me slightly about
what I’d be eating and that sort of stuff, my diet, but
I’m not really a fussy eater so.
(DNA, positive, 03, time 1)
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different to how I do now because I am almost
convinced that that is the case anyway. It’s something
that I’ve lived with for a long time anyway. It doesn’t
really affect my health, you know day to day living.
(DNA, positive, 04, time 1)
This sense of simply getting on with the routine of
their lives was also reflected in their responses after the
test results. Again, whether the test was a genetic one or
not did not seem to make any difference.
As I say I don’t, it’s not something I’m really worried
about. I mean. . . I felt sort of positive that I wouldn’t
have it prior to the test. . .I’ve not really sort of dwelled
on it and sort of. . . yeah I’ve just sort of got on with
life basically.
(NonDNA, negative, 07, time 2)
(Interviewer: So how did you feel about your results
when you received them at the last appointment?)
Okay. I’ve known that I’ve had high cholesterol so I
was just pleased that they were increasing the dosage
(of Pravastatin).
(NonDNA, positive, 09, time 2)
I continue to do what I did anyway, which is watch my
diet and exercise regularly, and since then, obviously,
medication’s come onboard, so I’m fine with it.
(NonDNA, positive, 01, time 3)
I was expecting them so I wasn’t too upset. I wasn’t too
shocked or alarmed. I was kind of thinking I was going
to have them because of my mum and my sister
having them so I was quite well prepared for it. I’m
alright about it. I just accept the fact that I’ve got it
and just deal with it and make it not an issue in my
personal health.
(DNA, positive, 10, time 2)
Reduction of uncertainty
While the diagnosis did not seem to have a great impact
on these patients’ lives, they all had immediate reactions
which revealed that they were managing to adjust and
incorporate this new information into their biographical
cognitive framework. For example, many patients
reported that the diagnostic test, whatever its outcome,
had reduced the uncertainty that surrounded their
health status. While most reported clear expectations ofwhat the test might reveal, the actual result removed any
residual doubt. Whether a positive or negative test re-
sult, from either a genetic or non-genetic test, the re-
moval of uncertainty was generally seen as a good thing,
simply because certainty was preferable.
It’s best for me knowing now that I haven’t got to sort
of alter my lifestyle greatly to sort of try and fight
something, through no fault of my own.
(NonDNA, negative, 06, time 2)
(Interviewer: So what do your test results mean for
your health now?) They’re peace of mind you know.
(NonDNA, negative, 08, time 3)
I guess it’s a relief in a funny way because I had an
answer to what was quite a surprising medical
condition that I had, which is the stroke that I
had. . .So at least I know now and can take
preventative measures
(NonDNA, positive, 06, time 2)
I mean the whole experience has been a positive thing.
Obviously it’s quite scary to start with because you
don’t really want to know but it is better to know and
to get it sorted. I am relieved.
(DNA, negative, 02, time 2)
Lifestyle reinforcement
Another effect of the diagnosis was to incentivise
patients to maintain healthy lifestyles. This was particu-
larly salient for those receiving a positive diagnosis but
even in those receiving a negative report there was still
an increased awareness that healthy lifestyles were of
general benefit. In this way, diagnosis had a reinforcing
effect on health-related behaviours but generally seemed
not to induce new ones (other than changes to pre-
scribed medication).
Receipt of a negative test result led patients to reflect
upon their past and future behaviour. Those undergoing
a non-genetic assessment perceived that the risk of hav-
ing FH was reduced by the adoption of a healthy lifestyle
and the prognosis of the disease improved by a healthy
lifestyle. The failure to diagnose FH was thus perceived
as a vindication of their prior behaviour.
(Interviewer: What do these test results mean for your
health now?) That I carry on eating a healthy diet
and making sure I get exercise. I have to continue to
monitor my diet and try to keep healthy.
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It just means that I am obviously doing something
right and carry on the way I’m going. . . . if I just carry
on doing what I’m doing, keep exercising the way I do
and eat what I eat then I should be okay.
(NonDNA, negative, 06, time 2)
Well it shows that I am looking after myself.
(NonDNA, negative, 07, time 2)
It just reinforces that I want to continue to have a
healthy lifestyle.
(NonDNA, negative, 10, time 3)
Patients who had a negative diagnosis of FH through a
genetic test also attributed their negative diagnoses to
healthy living.
(Interviewer: What does the result mean to you in
terms of your health?) That I'm looking after myself,
that I'm eating properly, looking after my cholesterol.
Just means I need to continue what I’m doing, try and
stay away from the fatty foods and the unhealthy stuff
and maintain a healthy balanced diet.
(DNA, negative, 04, time 2)
Perhaps it has something to do with the lifestyle that
I've had, because up until like my 30s I was quite an
active person, I was quite fit, I was in the Army so I
suppose that helps. Whereas my dad he. . . I think the
last time he did anything really physical like that he
was at school.
(DNA, negative, 06, time 2)
I was always interested in sports as a youngster and
I’ve kept myself busy, looked after myself and so it
didn’t allow any sort of fat, if you like, to develop as
much.
(DNA, negative, 06, time 3)
Patients with negative diagnoses in both genetic and
non-genetic assessment groups intended to continue to
behave healthily in the future.
Just again watch what I’m eating really, you know,
continue to watch what I’m eating even though I
haven’t got it hereditary, you know you can still get itby eating, you know, unhealthily and it’s basically just
a healthy lifestyle. Just to continue trying to be healthy
and live a healthy lifestyle and eat healthily.
(NonDNA, negative, 04, time 2)
I wouldn’t say so, no but you can’t be too complacent
as in oh right I’ve not got it so I can go out and be
really silly and eat lots of silly things, you know you’ve
still got to be realistic and think ‘well you know I still
have to watch what I eat and do exercise’.
(NonDNA, negative, 09, time 2)
I will do my damnedest to have more exercise, which I
am very lazy now because I do tend to use the car to
go everywhere even up to the shop. In the past where I
couldn't drive it was quite naive, ride a bike or walk. I
must admit I have been quite good in the last month
or so, I do walk a lot more.
(DNA, negative, 03, time 2)
Try not to eat too much junk and get more healthy.
(DNA, negative, 05, time 2)The importance of FH relative to other conditions
The way in which the diagnosis (or non-diagnosis) was
incorporated into everyday lives was also illustrated by
a few patients who in the course of the interview
revealed that they had other illnesses which were
clearly of greater salience. For example, one patient
had been diagnosed with hepatitis while another had a
long-standing problem of psoriasis. In both cases it
was clear that these individuals viewed their other ill-
ness as more important than their risk of heart dis-
ease.
Unfortunately, I've got other problems so, although I've
got rid of that I've got other things to contend with
anyway. Yeah I'm pleased with that (the FH result)
but I've found out I've got Hep C so I go for injections
for that so yeah.
(DNA, negative, 03, time 3)
However, the process of engagement with clinical ser-
vices and accompanying focus on their health associated
with FH testing and treatment appeared to enable
patients to have greater confidence about addressing
other medical concerns. The patient with psoriasis
expressed this as follows.
Hollands et al. BMC Medical Genetics 2012, 13:87 Page 7 of 9
http://www.biomedcentral.com/1471-2350/13/87One thing that’s changed in my life is that I seem to be
sort of at the doctors a lot. And now when you find out
there is something wrong I think that I am a little
more aware of my health. If something happens I do
tend to think “I’ll go and see the doctor about that.”
and get it sorted out. So I have psoriasis and things
like that, so I try and pay more attention to that and
see if I can sort it out. But it’s interesting, I feel like at
the age of 40 I’ve had an extremely good medical, I
mean they’ve taken blood tests for everything you can
think of.
(NonDNA, positive, 02, time 3)
Another patient had recently had a triple heart bypass
and it was clear that the FH diagnosis was just a part of
the overall recovery process and not a predominant
focus.
(Interviewer: Do you talk about FH with your partner
or family?) Not since the bypass and that, it’s just the
road to recovery really, I haven’t really mentioned. . .
we haven’t really discussed it.
(DNA, positive, 09, time 2)
Overall, the type of test did not seem to affect the sali-
ency of other illnesses.Social impact
While the results of the diagnostic tests did not seem to
have a discernible direct impact on patients’ self-percep-
tions, it did at times seem to affect their relationships
with others. Once they had a positive diagnosis of FH,
their social status changed in as much as their strict life-
style regime was now based on a formal medical cat-
egory rather than a general motivation to keep healthy.
Some patients were therefore surprised when they
revealed their FH status (or even their appointment for
testing) to others to find general level of concern which
was far greater than their own. These effects did not ap-
pear to differ by the method of testing.
I’m quite a relaxed person but it was the reaction from
my peers, my friends and my wife. I’m not secretive
but I don’t go on about things very much like that. So
when I said I had this appointment and stuff like that
at dinner parties and at the pub with friends they
were more shocked, they were like “Oh my God”. The
fact that I was in any way not perfectly healthy was, it
was shocking to them.
(NonDNA, positive, 02, time 1)Several patients described difficulty explaining to
others their dietary choices in social situations. This at
times caused some embarrassment as they have to ex-
plain their behaviour in terms of having a medical condi-
tion rather than being fussy or needlessly watchful.
I mean initially when you say you’re on a low fat diet
people assume you’re trying to lose weight or
something and they can be quite negative. I’m quite
slim and they assume I’m being stupid and trying to
starve myself.
(DNA, positive, 02, time 2)
Some people comment on the things I eat. And then
I’m like “well actually I have to eat this because I’ve
got FH and I have to watch my diet”.
(DNA, positive, 07, time 3)
At other times, revealing the diagnosis of high choles-
terol led peers to comment negatively on the behaviour
of the patient.
If you are in discussions with us and you sort of
mention that you have high cholesterol, immediately
everybody says well it’s due to eating rubbish, it’s due
to eating fatty foods, no exercise, things like that. So
people assume that because you say you’ve got high
cholesterol it’s as a result of things that you’ve done.
(NonDNA, positive, 01, time 2).
Another patient found that having a positive diagnosis
for FH allowed them to respond to similar negative
comments about their health and behaviour.
I guess the benefit of being able to say “I’ve got FH”
means that you can say, “actually it’s not just that I’m
a fat boy” but yeah you can actually say “well actually
it’s not” because people say, “well if you ate salad and
did some exercise” and you can say “actually, it’s not
just that it’s. . .”.
(NonDNA, positive, 03, time 2)
Discussion
Receipt of a formal (i.e. clinically determined and intended
as definitive) diagnosis of familial hypercholesterolaemia
(FH) had minimal impact on these patient's lives. The
dominant response was one of continuity of both their
beliefs and behaviour. Some patients did report some
minor effects on their social relationships, broadly consist-
ent with the limited prior research into the specific impact
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difference in impact for those whose diagnostic assess-
ment included a genetic test compared with those whose
assessment was made without genetic testing. These find-
ings echo those from the comparison study of FH diagno-
sis from the perspective of health practitioners [19]. In
that context, while practitioners appeared aware of and
interested in the genetic element of FH, genetic testing
did not play a major part in the diagnostic process.
These findings fit within psychological theories of self-
regulation that describe the ways in which individuals
are able to maintain emotional consistency whilst deal-
ing with threats to their well-being [20]. Within this
study, there was evidence of individuals both engaging
in behaviours to reduce threats to health and also adapt-
ing cognitively to minimise the impact of the informa-
tion that was presented to them. Regarding the former
strategy, largely irrespective of the nature of their results,
patients were found to use the results as evidence of the
need to maintain healthy lifestyles, for example by en-
gaging in physical activity and monitoring dietary intake.
Regarding the latter, prior to testing patients were typic-
ally highly aware of their increased risk and of the nature
of the testing process, and often had successfully pre-
dicted the outcome, allowing for relatively ready adjust-
ment. They were commonly able to assimilate and
integrate the test result, and even derive a sense of relief,
again usually irrespective of the outcome of the assess-
ment, in part due to regarding it as a means to reduce
or remove ongoing uncertainty about their health.
Whilst the scope of the data collection process used in
the current study was substantial, the results inevitably
raise a question of the extent to which they can be gen-
eralised beyond the current context. To begin to address
this, it is instructive to examine the results in the light of
a series of systematic reviews which have assessed the
impact of genetic test results on cognitions, emotions
and behaviour. These reviews display considerable
consistency in suggesting that the receipt of such results
typically has little discernible impact. For example, a
Cochrane Review that examined behavioural effects of
DNA-based disease risk assessment [21] found little evi-
dence of any effect on risk-reducing health behaviours,
running contrary to the commonly-voiced belief that
such risk assessments motivate behavioural changes. A
systematic review of the emotional impact of screening
(including genetic screening) for disease risk [22] found
no evidence of enduring adverse effects on depression,
anxiety, general distress or quality of life. Finally, regard-
ing impact on patients’ cognitions, Collins and collea-
gues [23] found no effects of personalised genetic risk
information on perceived control over the risk in either
the short or longer term, with fatalistic responses not
seemingly being engendered. In sum, in spite ofwidespread beliefs amongst healthcare providers that
genetic screening is likely to have systematic and potent
emotional and behavioural effects [24-26] the evidence
increasingly suggests that this is unlikely to be the case.
Instead of a generalisable pattern irrespective of the
degree of conferred risk, impact could be a function of
the size of the conferred risk. Much of the evidence to
date, including that derived from the previously
described systematic reviews, has focused primarily on
common complex diseases (e.g. cancers, diabetes, heart
disease). For most such conditions, the penetrance of
implicated gene variants is relatively low [27], but if
penetrance is high and thus the presence of a specific
gene variant indicates a high probability of disease, then
a greater impact may be expected. Importantly, however,
the current study did not find evidence for this in the
context of FH, which is linked to genetic variants of high
penetrance, conferring cumulative risks of coronary
heart disease of more than 50% by age 50 in men and at
least 30% by age 60 in women [28,29]. An additional fac-
tor to consider is the severity of health consequences
associated with any genetic result. Again, there is no evi-
dence of such effects. For example, an aforementioned
review included five studies of the emotional conse-
quences of predictive genetic testing for Huntington’s
disease, which has very serious health consequences and
is not regarded as treatable (unlike FH) [6] found no evi-
dence of adverse emotional consequences in individuals
found to be carriers.Conclusions
Giving first and second degree relatives a formal FH
diagnosis had minimal impact on their lives. Using an
innovative design, it was also possible to show that there
was no discernible difference between those for whom
genetic tests formed part of the diagnostic procedures
compared with those for whom they did not. This sug-
gests that concerns about the use of genetic testing in
this context are unfounded, a conclusion that echoes
findings from studies in this and other health contexts.
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